StemSynergy Therapeutics (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer. We target the cancer stem/initiating cell (CSC) populations, with the overall aim of eliminating tumor growth. We have breakthrough technologies in modulating CSC pathways, primarily Wnt, Notch, and Myc signaling. With a multi-pronged scientific approach and a number of agents targeting these pathways, SSTI is well positioned to address critical unmet needs in cancer treatment.